title: [Telithromycin, first ketolide].
abstract: Telithromycine is the first ketolide on the market. Its characteristics are the two sites fixation on the bacterial ribosomia and and as a consequence a good activity on the majority of penicillin and macrolides resistant bacteria, included S. pneumonia and S. pyogenes. Telithromycine represents an alternative to beta-lactames and moxifloxacine to treat communautary pneumonia, bacterial pharyngoamygdalitis, suppurative sinusitis and bronchitis. There are nevertheless problems with drugs interactions and risk of resistance development.
authors.affiliation: Service des Maladies Infectieuses, C.H.U. Saint-Pierre, U.L.B.
authors.forename: Y
authors.initials: Y
authors.lastname: Van Laethem
authors.forename: J
authors.initials: J
authors.lastname: Sternon
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D048628:Ketolides; D018942:Macrolides / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D048628:Ketolides; D018942:Macrolides; C106791:telithromycin